Products

Medomics Flu and 2021 Novel Contagious Virus Combined Antigen Detection Test

China Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test, Find details about China Medical, Test Kit from Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test

HS Code
3002150090
HS Code
3002150090
Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test
Medomics Flu A&B and Novel Virus Antigen Test Kit (LFIA) is used to qualitatively detect influenza virus type A, influenza virus typeB and novel virus antigens in human samples in vitro. 2019 Novel Virus belongs to the order Nidovirales under the Coronaviridae family with 4 genera: α, β, γ and δ. The α and β genera are only pathogenic to mammals, while γ and δ genera mainly causes bird infections.

Since Flu A&B and 2019 novel virus have similar symptoms and routes of infection, the kit has important clinical significance in identifying them.
 
Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test
Key Features:

Sensitivity: >95%
Specificity: 100%
Reaction Time: 10mins
Sample: nasopharyngeal swab specimens
Storage temperature: 4-30ºC
Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test
Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test



About Medomics
Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test
Jiangsu Medomics Medical Technology Co., Ltd., is located at Biotech and Pharmaceutical Valley of the National Jiangbei New Area, Nanjing, Jiangsu Province. It is an international high-tech enterprise driven by innovation in the area of medical devices R&D, production and sales. Medomics focuses on diagnosis of microorganisms, tumors and some rare diseases, mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and automatic instruments.  

Medomics owns two R&D centers in China and the US, independent intellectual property rights of fluorescent staining technology, protein labeling technology, time-resolved immunofluorescence detection technology, image processing and analysis technology and other innovative technology platforms, as well as a total of more than 10,000 square meters of GMP purification production workshop that meets the product standards of FDA, CE and CFDA. Until now, Medomics has more than 100 employees across the world and R&D personnel accounts for over 50%. Medomics also has a multidisciplinary expert team with abundant experience in the industry, including senior experts in immunology, microbiology, applied physics, polymer materials, medical imaging, optical systems, etc. The members of the technical team are led by doctors from many famous institutions, such as Osaka University, North Carolina University, University of Nebraska Lincoln, Zhejiang University, Sichuan University and other institutions.

Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test
Contact Medomics
Medomics Flu and 2019 Novel Contagious Virus Combined Antigen Detection Test

You Might Also Like